Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from August 13, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 11, 2025 — -2.1% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$48.89 – $50.36Entry zone — fair-value band

$50.19Published — price the day we called it

$58.56Target — the price the thesis aimed for

$62.32Peak — highest point inside the window, not a realized return

$49.15Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 36 days.

At window close

-2.1%

realized, from the publication price to the last close inside the window

Peak gain

+24.2%

peak, from the publication price — not a realized return

S&P 500, same window

+6.2%

SPY over the identical days, dividend-adjusted

Window close

$49.15

last close inside the window, ended November 11, 2025

Peak price

$62.32

peak on September 19, 2025 — not a realized return

Days to target

The thesis — published August 13, 2025

Predicted growth

+18%

over the measurement window

Target price

$58.56

the price the thesis aimed for

Entry zone

$48.89 – $50.36

the fair-value band we waited for

Price at publication

$50.19

published August 13, 2025

Confidence

74%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk leads in diabetes and weight-loss medicines and demand stays strong. The stock has pulled back, and the recent average price is trending down, but short-term signs suggest it may be near a turn. News points to more people needing care, and rivals launching similar drugs confirm the market is growing. Easing in slowly on weakness aims for a rebound over the next 0-3 months as confidence and buying interest recover.

Primary drivers

Leader in diabetes and weight drugs, with steady long-term demand globally
Recent slide looks overdone, setting up a potential near-term bounce soon
More people being treated for diabetes grows the potential customer base
Price momentum likely to improve after this pullback as buyers return

How it played out

NVO: target reached in 36 days

Lyra published NVO at $50.19 on 2025-08-13, with expected growth of 18% over a short-term window. The thesis pointed to Novo Nordisk's position in diabetes and weight-loss medicines, steady demand, a pullback that looked overdone, more people needing diabetes care, and a possible rebound as buyers returned.

Inside the window, the stock reached a peak of $62.32 on 2025-09-19. That was above the $58.56 target, with a peak gain of 24.2%, and the target was reached in 36 days. By 2025-11-11 it ended at $49.15. The thesis played out, then the move faded.

What happened during the window

On 2025-09-10, Novo Nordisk announced a restructuring that included 9,000 job cuts and a lower 2025 profit forecast. On 2025-09-18, the company reported trial results for an oral Wegovy version, with adherent patients losing 16.6% of body weight over 64 weeks.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals